Third Harmonic Bio, Inc.

Equities

THRD

US88427A1079

Biotechnology & Medical Research

Delayed Nasdaq Other stock markets 01:25:36 24/05/2024 am IST			5-day change	1st Jan Change
14 ^USD	-6.23%		-1.97%	+27.16%

20/05	Third Harmonic Bio Insider Sold Shares Worth $331,066, According to a Recent SEC Filing	MT
15/05	Third Harmonic Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	CI

Third Harmonic Bio, Inc. Announces the Transition of Adrian S. Ray from Chief Scientific Officer to Scientific Advisor, Effective November 1, 2023

October 31, 2023 at 05:31 pm IST

Third Harmonic Bio, Inc. announced the transition of Adrian S. Ray, Ph.D., from Chief Scientific Officer to Scientific Advisor, effective November 1, 2023. In his new role, Dr. Ray will continue support the company?s Investigational New Drug (IND) application for THB335, which is expected to be filed during the first half of 2024.

Latest news about Third Harmonic Bio, Inc.

Third Harmonic Bio Insider Sold Shares Worth $331,066, According to a Recent SEC Filing	21/05	MT
Third Harmonic Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	15/05	CI
Third Harmonic Bio, Inc. Announces the Appointment and Promotion of Key Executive Leaders to the Organization	15/05	CI
Third Harmonic Bio, Inc. Appoints Geoff Mcdonough to Its Board of Directors	28/03	CI
Third Harmonic Bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	26/03	CI
Third Harmonic Bio Names Christopher Murphy as Chief Financial, Business Officer	04/01	MT
Third Harmonic Bio Appoints Christopher Murphy as Chief Financial Officer	04/01	CI
Third Harmonic Bio, Inc. Appoints Christopher Murphy as Chief Business Officer	04/01	CI
Third Harmonic Bio, Inc.(NasdaqGM:THRD) added to NASDAQ Biotechnology Index	18/12	CI
Third Harmonic Bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	09/11	CI
Third Harmonic Bio, Inc. Announces the Transition of Adrian S. Ray from Chief Scientific Officer to Scientific Advisor, Effective November 1, 2023	31/23/31	CI
Third Harmonic Bio, Inc. Announces Resignation of Robert Ho as Chief Financial Officer, Effective November 10, 2023	31/23/31	CI
Morgan Stanley Adjusts Price Target on Third Harmonic Bio to $7 From $5, Maintains Equalweight Rating	11/23/11	MT
Third Harmonic Bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	10/23/10	CI
Third Harmonic Bio, Inc Announces Next-Generation Oral KIT Inhibitor Product Candidate THB335	25/23/25	CI
Third Harmonic Bio, Inc.(NasdaqGM:THRD) dropped from Russell Microcap Growth Index	23/23/23	CI
Third Harmonic Bio, Inc.(NasdaqGM:THRD) dropped from Russell 3000E Growth Index	23/23/23	CI
Third Harmonic Bio, Inc.(NasdaqGM:THRD) dropped from Russell 2500 Growth Index	23/23/23	CI
Third Harmonic Bio, Inc.(NasdaqGM:THRD) dropped from Russell 3000 Growth Index	23/23/23	CI
Third Harmonic Bio, Inc.(NasdaqGM:THRD) dropped from Russell Small Cap Comp Growth Index	23/23/23	CI
Third Harmonic Bio, Inc.(NasdaqGM:THRD) dropped from Russell 2000 Growth Index	23/23/23	CI
Third Harmonic Bio, Inc. Ratifies the Appointment of Deloitte & Touche LLP as the Independent Registered Public Accounting Firm for the Fiscal Year Ending December 31, 2023	09/23/09	CI
Third Harmonic Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	12/23/12	CI
Certain Options of Third Harmonic Bio, Inc. are subject to a Lock-Up Agreement Ending on 14-MAR-2023.	14/23/14	CI
Certain Common Stock of Third Harmonic Bio, Inc. are subject to a Lock-Up Agreement Ending on 14-MAR-2023.	14/23/14	CI

Chart Third Harmonic Bio, Inc.

Duration

Period

More charts

Company Profile

Third Harmonic Bio, Inc. is a biopharmaceutical company. The Company is focused on advancing the next wave of medicine for inflammatory diseases through the development of novel, small-molecule inhibitors of KIT, a cell surface receptor that serves as the master regulator of mast cell function and survival. It is developing medicine for the treatment of inflammatory diseases, including dermal, respiratory, and gastrointestinal diseases. Mast cells are a part of the immune system, and dysfunctional mast cell activity has been implicated in the pathophysiology of a broad range of inflammatory disorders including urticaria, asthma and gastrointestinal disorders, among others. The Company is advancing its lead product candidate, THB335, for the treatment of multiple mast cell-driven inflammatory diseases of the skin, airway and gastrointestinal tract. THB335 is a potent, highly selective, oral small molecule KIT inhibitor with a promising preclinical product profile.

Sector

Biotechnology & Medical Research

Calendar

06/06/2024 - Annual General Meeting

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

14.93 USD

Average target price

13.5 USD

Spread / Average Target

-9.58%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
THIRD HARMONIC BIO, INC.	+27.16%	611M
VERTEX PHARMACEUTICALS INCORPORATED	+10.72%	115B
REGENERON PHARMACEUTICALS, INC.	+11.51%	106B
BIONTECH SE	-6.22%	24.69B
ARGENX SE	-2.33%	21.97B
GENMAB A/S	-6.03%	19.27B
BEIGENE, LTD.	-13.27%	17.56B
WUXI APPTEC CO., LTD.	-40.50%	17.32B
NEUROCRINE BIOSCIENCES, INC.	+6.48%	14.03B
SAREPTA THERAPEUTICS, INC.	+31.59%	12.13B

Bio Therapeutic Drugs